Evaluation of Dihydroxyanthracenedione (DHAD) in Acute Leukemia

Closed

Phase

Published

Abbreviated Title

Activated

10/22/1980

Closed

09/10/1982

Publication Information Expand/Collapse

1993

Mitoxantrone (dihydroxyanthracenedione) in acute leukemia: An evaluation of two treatment schedules by the Southwest Oncology Group.

JH Saiki;WJ Stuckey;JW Athens;BL Tranum;E Van Slyck;DD Von Hoff IND 11:197-200

1983

Two-dose schedules of Dihydroxyanthracenedione (DHAD) in acute leukemia - A Southwest Oncology Group study

J Saiki;W Stuckey;B Tranum;R O'Bryan;S Rivkin;J Athens ASCO #C-675

Mitoxantrone hydrochloride in hematologic malignancies: Southwest Oncology Group Phase II studies.

CA Coltman Jr;JH Saiki;FJ Panettiere;SP Balcerzak;RL Stephens;FS Morrison;DO Dixon;DD Von Hoff In: 3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy (Brussels, October 15-17, 1981) M Rozencweig, DD Von Hoff, MJ Staquet, eds. New Anticancer Drugs: Mitoxantrone and Bisantrene. New York: Raven Press 115-124.

1981

Mitoxantrone Hydrochloride (NSC-30179) in hematologic malignancies

CA Coltman Jr;JH Saiki;FJ Panettiere;SP Balcerzak;RL Stephens;FS Morrison;DO Dixon;DD Von Hoff 3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy (Brussels)